Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11346251 | 0.85 | GAA (0.53) | ALDH1A1CYP1A2CYP2C9GAAPTPRC | |
| SCHEMBL6890669 | 0.82 | GAA (0.50) | ALDH1A1CYP1A2CYP2C9GAAPTPRC | |
| SCHEMBL1562501 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL13140916 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL14950485 | 0.80 | GAA (0.63) | ALDH1A1CYP1A2CYP2C9GAAPTPRC | |
| SCHEMBL16726879 | 0.80 | RECQL (0.48) | ALDH1A1CYP1A2CYP2C9GAAPTPRC | |
| SCHEMBL16726882 | 0.80 | GAA (0.63) | ALDH1A1CYP1A2CYP2C9GAAPTPRC | |
| SCHEMBL5419285 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL13140937 | 0.79 | PTPN1 (0.44) | ALDH1A1CYP1A2CYP2C9MEN1MAPT | |
| SCHEMBL8610167 | 0.78 | ALDH1A1 (0.65) | ALDH1A1CYP1A2CYP2C9GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-9688663-B2 | Crosslinking reagents, methods, and compositions for studying protein-protein interactions | Cell Mosaic, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | CELLMOSAIC INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0203271-A2 | Antibacterial compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-12-03 | — | — | EP | disclosed |
| WO-1986005183-A1 | ANTIBACTERIAL COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-09-12 | — | — | WO | disclosed |
| EP-0187500-A1 | Monobactams | THE UPJOHN COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |
| EP-0135194-A1 | Azetidinones and their production | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0021519-B1 | OXYIMINO-SUBSTITUTED CYCLOPROPANE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE, PESTICIDAL COMPOSITIONS AND THEIR USE AS AND IN THE MANUFACTURE OF PESTICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-07-18 | — | — | EP | disclosed |
| US-4281183-A | INSECTICIDES, PESTICIDES | SHELL OIL COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| EP-0021519-A2 | Oxyimino-substituted cyclopropane compounds, process for their manufacture, pesticidal compositions and their use as and in the manufacture of pesticides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-01-07 | — | — | EP | disclosed |
| US-4237123-A | INSECTICIDES, MITICIDES | SHELL OIL COMPANY (US) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | ALDH1A1 345/4885CYP1A2 2080/4885CYP2C9 2058/4885 |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | PBDC1, RCSD1, STUB1 | ALDH1A1 2921/4885CYP1A2 4010/4885CYP2C9 2319/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | ALDH1A1 2753/4885CYP1A2 4661/4885CYP2C9 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.